Source MS Trust:
The European Commission (EC) has granted marketing authorization for cladribine (Mavenclad)for the treatment of adults with highly active relapsing multiple sclerosis. This follows a recommendation from the European Medicines Agency in June that a licence should be granted.
Source MS Trust:
The European Commission (EC) has granted marketing authorization for cladribine (Mavenclad)for the treatment of adults with highly active relapsing multiple sclerosis. This follows a recommendation from the European Medicines Agency in June that a licence should be granted.
Cladribine will now need to be appraised by NICE and the SMC to determine NHS availability in the UK. NICE has started the process and the MS Trust is contributing to the appraisal. A decision from NICE is expected to be published in February 2018, with the drug potentially available on the NHS in England and Wales three months later. Read on.
